Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study

Archive ouverte

Shili-Masmoudi, Sarah | Sogni, Philippe | Ledinghen, Victor De | Esterle, Laure | Valantin, Marc-Antoine | Poizot-Martin, Isabelle | Simon, Anne | Rosenthal, Eric | Lacombe, Karine | Pialoux, Gilles | Bouchaud, Olivier | Gervais-Hasenknoff, Anne | Goujard, Cécile | Piroth, Lionel | Zucman, David | Dominguez, Stephanie | Raffi, Francois | Alric, Laurent | Bani-Sadr, Firouze | Lascoux-Combe, Caroline | Garipuy, Daniel | Miailhes, Patrick | Vittecoq, Daniel | Duvivier, Claudine | Aumaitre, Hugues | Neau, Didier | Morlat, Philippe | Dabis, Francois | Salmon, Dominique | Wittkop, Linda

Edité par CCSD ; Public Library of Science -

International audience. BackgroundThe association between liver stiffness measurements (LSM) and mortality has not been fully described. In particular the effect of LSM on all-cause mortality taking sustained virological response (SVR) into account needs further study.MethodsHIV/HCV participants in the French nation-wide, prospective, multicenter ANRS CO13 HEPAVIH cohort, with ≥1 LSM by FibroScan (FS) and a detectable HCV RNA when the first valid FS was performed were included. Cox proportional hazards models with delayed entry were performed to determine factors associated with all-cause mortality. LSM and SVR were considered as time dependent covariates.Results1,062 patients were included from 2005 to 2015 (69.8% men, median age 45.7 years (IQR 42.4–49.1)). 21.7% had baseline LSM >12.5 kPa. Median follow-up was 4.9 years (IQR 3.2–6.1). 727 (68.5%) were ever treated for HCV: 189 of them (26.0%) achieved SVR. 76 deaths were observed (26 liver-related, 10 HIV-related, 29 non-liver-non-HIV-related, 11 of unknown cause). At the age of 50, the mortality rate was 4.5% for patients with LSM ≤12.5 kPa and 10.8% for patients with LSM >12.5 kPa. LSM >12.5 kPa (adjusted Hazard Ratio [aHR] = 3.35 [2.06; 5.45], p<0.0001), history of HCV treatment (aHR = 0.53 [0.32; 0.90], p = 0.01) and smoking (past (aHR = 5.69 [1.56; 20.78]) and current (3.22 [0.93; 11.09]) versus never, p = 0.01) were associated with all-cause mortality independently of SVR, age, sex, alcohol use and metabolic disorders.ConclusionAny LSM >12.5 kPa was strongly associated with all-cause mortality independently of SVR and other important covariates. Our results suggest that close follow-up of these patients should remain a priority even after achieving SVR.

Suggestions

Du même auteur

All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus–coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13–HEPAVIH Cohort

Archive ouverte | Sogni, Philippe | CCSD

International audience. BACKGROUND:Human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients with cirrhosis have long been considered to be difficult to treat, and real-life efficacy and toleran...

Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort

Archive ouverte | Billa, Oumar | CCSD

International audience. Compared to the general population, HIV-infected patients are at higher risk of developing non-AIDS-defining cancers. Chronic HCV infection has also been associated with a higher risk than th...

Efficacy and Safety of Direct-Acting Antiviral Regimens in HIV/HCV-co-infected Patients \textendash French ANRS CO13 HEPAVIH Cohort

Archive ouverte | Piroth, Lionel | CCSD

International audience

Chargement des enrichissements...